{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:30:14Z","timestamp":1792218614696,"version":"4.4.0"},"reference-count":12,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>During administration of chemotherapies, disconnection presents risks for nurses. Thus, it is recommended to flush the infusion line with solvent to reduce this risk and ensure that the entire dose is administered. Objectives of this study were to evaluate flushing practices and to investigate the efficiency of flushing, according to the type of hospitalization, in hospitalization (HU) or day-care unit (DCU), for three drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Twenty secondary infusion lines were collected in five HU and 20 in two DCU. Flushing volumes were estimated by weighing solvent bags. The amount of residual drug was measured for secondary lines by mass spectrometry coupled with high-performance liquid chromatography.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Chemotherapies were administered by 26 nurses. All of infusion lines contained chemotherapy after flushing. Flushing volumes, residual concentrations and flushing efficiencies were significantly different between these two types of units. In contrast, flushing volumes administrated did not differ between chemotherapy drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Local recommendations are fully implemented in HU and partially in DCU. The use of small volumes in DCU is related to the patient length of stay, it may, also, be due to omitting the average tubing volume. All infusion lines still contained chemotherapy, including those with a flush volume much higher than recommended, showing that the risk of exposure persists. To achieve a rinse volume greater than 50 mL, it is necessary to use at least 100 mL. It is also important to insist on personal protective equipment and to consider closed safety system for administration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552231175820","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T01:36:36Z","timestamp":1685496996000},"page":"278-285","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Residual chemotherapy drugs after flushing infusion lines"],"prefix":"10.1177","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9522-6365","authenticated-orcid":false,"given":"Marie-Alix","family":"Marchal","sequence":"first","affiliation":[{"name":"Hospital Saint-Louis, Pharmacy, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Robert","sequence":"additional","affiliation":[{"name":"Hospital Saint-Louis, Pharmacy, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00eblle","family":"Pesqu\u00e9","sequence":"additional","affiliation":[{"name":"Hospital Saint-Louis, Pharmacy, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Jourdan","sequence":"additional","affiliation":[{"name":"Hospital Saint-Louis, Pharmacy, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8580-0044","authenticated-orcid":false,"given":"Paul","family":"Sessink","sequence":"additional","affiliation":[{"name":"Exposure Control Sweden AB, Bohus-Bj\u00f6rk\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Madelaine","sequence":"additional","affiliation":[{"name":"Hospital Saint-Louis, Pharmacy, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Levert","sequence":"additional","affiliation":[{"name":"Hospital Saint-Louis, Pharmacy, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"key":"bibr1-10781552231175820","unstructured":"National Institute for Occupational Safety and Health\n                      . NIOSH Alert: Preventing Occupational exposures to antineoplastic and other hazardous drugs in health care settings. Report, Centers for Disease Control and Prevention, Report No.: 2004-165, September 2004."},{"key":"bibr2-10781552231175820","volume":"28","author":"International Society of Oncology Pharmacy Practitioners","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"bibr3-10781552231175820","volume-title":"Pr\u00e9paration & Administration des M\u00e9dicaments \u00e0 Risques pour le Personnel et l\u2019Environnement","author":"Crauste-Manciet S","year":"2007"},{"key":"bibr4-10781552231175820","doi-asserted-by":"publisher","DOI":"10.1097\/01.NAJ.0000552583.69729.51"},{"key":"bibr5-10781552231175820","unstructured":"Exposure Control Sweden AB\n                      . ALC-MSMS methods for the analysis of cytotoxic drugs in air, wipe and urine samples, https:\/\/www.exposurecontrol.net\/about-us (accessed 9 April 2022)."},{"key":"bibr6-10781552231175820","volume-title":"Journ\u00e9es Euro-Pharmat","author":"Simon"},{"key":"bibr7-10781552231175820","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaa357"},{"key":"bibr8-10781552231175820","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31825a4d9c"},{"key":"bibr9-10781552231175820","unstructured":"MS 10 & Fresenius Kabi\n                      . https:\/\/france.ecatalogue-dm-vial-fresenius-kabi.com\/fr\/produits\/ms-10 (accessed 14 April 2022)."},{"key":"bibr10-10781552231175820","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000254"},{"key":"bibr11-10781552231175820","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecoenv.2018.09.002"},{"key":"bibr12-10781552231175820","first-page":"229","volume":"26","author":"Brun H","year":"2007","journal-title":"J Pharm Clin"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231175820","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552231175820","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231175820","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:28:27Z","timestamp":1777688907000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552231175820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,30]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1177\/10781552231175820"],"URL":"https:\/\/doi.org\/10.1177\/10781552231175820","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,30]]}}}